Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia

The present study aimed to determine the safety and activity of the histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia (WM). Eligibility criteria included patients with relapsed/refractory WM with any number of prior therapies. Patients rece...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Ghobrial, Irene M., Campigotto, Federico, Murphy, Timothy J., Boswell, Erica N., Banwait, Ranjit, Azab, Feda, Chuma, Stacey, Kunsman, Janet, Donovan, Amanda, Masood, Farzana, Warren, Diane, Rodig, Scott, Anderson, Kenneth C., Richardson, Paul G., Weller, Edie, Matous, Jeffrey
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2013
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3578951/
https://ncbi.nlm.nih.gov/pubmed/23287861
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-06-439307
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados